Welcome to our dedicated page for Genfit S.A. news (Ticker: GNFT), a resource for investors and traders seeking the latest updates and insights on Genfit S.A. stock.
GENFIT S.A. (GNFT) is a late-stage biopharmaceutical company focused on severe chronic liver diseases, with a particular emphasis on cholestatic conditions and acute-on-chronic liver failure (ACLF). News about GENFIT often centers on its clinical programs, licensing agreements, and regulatory milestones in these specialized areas.
One key news theme is the development of elafibranor, an oral, once-daily, first-in-class PPAR alpha/delta agonist being evaluated in the ELATIVE™ Phase III trial for primary biliary cholangitis (PBC). Coverage includes updates on trial progress, regulatory designations such as Breakthrough Therapy and Orphan Drug status, and GENFIT’s exclusive licensing agreement with Ipsen for the development, manufacturing, and commercialization of elafibranor in PBC, along with related financial terms and Ipsen’s equity investment in GENFIT.
Another recurring topic is GENFIT’s activity in ACLF and other severe liver conditions. This includes the initiation of a Phase I clinical program with nitazoxanide in ACLF and GENFIT’s out-licensing arrangement with Seal Rock Therapeutics for the development of an injectable formulation of SRT-015, a liver-selective ASK1 inhibitor, for acute liver disease including ACLF. News items may highlight the scientific rationale for these programs and the structure of associated milestone and royalty agreements.
Investors and observers following GNFT news can expect updates on clinical trial milestones, partnership developments, regulatory interactions, and business and financial reports referenced in GENFIT’s communications. Returning to this page provides a focused view of how GENFIT’s liver disease pipeline and collaborations evolve over time.
Summary not available.
Ipsen has secured global rights to develop and commercialize GENFIT's innovative treatment, elafibranor, aimed at Primary Biliary Cholangitis (PBC). The agreement provides GENFIT with an upfront payment of €120 million and potential milestone payments totaling €360 million, alongside royalties up to 20%. Ipsen will also acquire an 8% equity stake in GENFIT through a €28 million investment. The Phase III trial, ELATIVE™, is ongoing, with top-line data expected in early 2023, presenting a significant opportunity for both companies in addressing unmet medical needs in liver diseases.